Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ALLKNASDAQ:LRMRNASDAQ:PRAXNASDAQ:RLYB On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeALLKAllakos$0.33$0.33$0.22▼$1.56$29.74M0.151.22 million shsN/ALRMRLarimar Therapeutics$2.42-6.6%$2.32$1.61▼$11.20$165.83M0.79827,799 shs3.06 million shsPRAXPraxis Precision Medicines$41.63-1.7%$38.82$26.70▼$91.83$862.42M2.61381,048 shs229,162 shsRLYBRallybio$0.31+1.8%$0.32$0.22▼$1.60$12.76M-1.24123,131 shs106,863 shsTen Starter Stocks For Beginners to Buy NowJust getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceALLKAllakos0.00%0.00%0.00%+33.62%-70.35%LRMRLarimar Therapeutics0.00%-10.07%+38.50%+13.60%-68.14%PRAXPraxis Precision Medicines0.00%-4.42%+12.76%+12.28%+1.53%RLYBRallybio0.00%-5.40%-6.92%-49.59%-79.01%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationALLKAllakos2.7646 of 5 stars3.10.00.04.70.02.51.3LRMRLarimar Therapeutics2.7485 of 5 stars3.63.00.00.02.41.70.6PRAXPraxis Precision Medicines2.4525 of 5 stars4.42.00.00.01.11.70.0RLYBRallybio3.055 of 5 stars3.05.00.00.00.01.71.3Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceALLKAllakos 2.25Hold$2.00507.72% UpsideLRMRLarimar Therapeutics 3.11Buy$19.67712.67% UpsidePRAXPraxis Precision Medicines 2.80Moderate Buy$109.90163.99% UpsideRLYBRallybio 2.00Hold$10.003,106.16% UpsideCurrent Analyst Ratings BreakdownLatest PRAX, ALLK, LRMR, and RLYB Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/12/2025PRAXPraxis Precision MedicinesNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$80.006/2/2025PRAXPraxis Precision MedicinesOppenheimerSubscribe to MarketBeat All Access for the recommendation accuracy ratingSet Price TargetOutperform$97.005/7/2025PRAXPraxis Precision MedicinesChardan CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$80.005/5/2025PRAXPraxis Precision MedicinesWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetUnderperform ➝ Underperform$26.00 ➝ $28.005/5/2025PRAXPraxis Precision MedicinesNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$80.00 ➝ $80.005/1/2025PRAXPraxis Precision MedicinesHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$105.00 ➝ $105.004/15/2025RLYBRallybioJones TradingSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Hold4/13/2025RLYBRallybioEvercore ISISubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeStrong-Buy ➝ Hold4/9/2025RLYBRallybioHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Neutral4/8/2025PRAXPraxis Precision MedicinesNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$85.00 ➝ $85.004/8/2025RLYBRallybioCitizens JmpSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeStrong-Buy ➝ Hold(Data available from 6/23/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookALLKAllakosN/AN/AN/AN/A$1.93 per shareN/ALRMRLarimar TherapeuticsN/AN/AN/AN/A$2.69 per shareN/APRAXPraxis Precision Medicines$8.55M99.18N/AN/A$23.90 per share1.74RLYBRallybio$640K20.28N/AN/A$1.49 per share0.21Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateALLKAllakos-$185.70M-$1.32N/AN/AN/AN/A-140.87%-86.22%8/6/2025 (Estimated)LRMRLarimar Therapeutics-$80.60M-$1.49N/AN/AN/AN/A-52.48%-46.08%8/6/2025 (Estimated)PRAXPraxis Precision Medicines-$182.82M-$10.72N/AN/AN/A-2,137.48%-50.42%-46.74%8/12/2025 (Estimated)RLYBRallybio-$57.78M-$1.09N/AN/AN/A-5,682.19%-72.31%-64.78%8/7/2025 (Estimated)Latest PRAX, ALLK, LRMR, and RLYB EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/8/2025Q1 2025RLYBRallybio-$0.21-$0.21N/A-$0.21N/A$0.21 million5/2/2025Q1 2025PRAXPraxis Precision Medicines-$3.20-$3.29-$0.09-$3.29$0.20 millionN/A4/30/2025Q1 2025LRMRLarimar Therapeutics-$0.42-$0.46-$0.04-$0.46N/AN/A3/24/2025Q4 2024LRMRLarimar Therapeutics-$0.29-$0.45-$0.16-$0.45N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthALLKAllakosN/AN/AN/AN/AN/ALRMRLarimar TherapeuticsN/AN/AN/AN/AN/APRAXPraxis Precision MedicinesN/AN/AN/AN/AN/ARLYBRallybioN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioALLKAllakosN/A6.086.08LRMRLarimar TherapeuticsN/A7.487.48PRAXPraxis Precision MedicinesN/A8.448.44RLYBRallybioN/A14.6814.68Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipALLKAllakos84.64%LRMRLarimar Therapeutics91.92%PRAXPraxis Precision Medicines67.84%RLYBRallybio90.34%Insider OwnershipCompanyInsider OwnershipALLKAllakos16.12%LRMRLarimar Therapeutics4.50%PRAXPraxis Precision Medicines2.70%RLYBRallybio8.70%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableALLKAllakos19090.38 million74.94 millionOptionableLRMRLarimar Therapeutics3064.03 million61.15 millionOptionablePRAXPraxis Precision Medicines11020.37 million19.82 millionOptionableRLYBRallybio4041.61 million37.99 millionNot OptionablePRAX, ALLK, LRMR, and RLYB HeadlinesRecent News About These CompaniesRallybio Initiates Dosing in RLYB116 Phase 1 Confirmatory Pharmacokinetic/Pharmacodynamic StudyJune 13, 2025 | finance.yahoo.comRallybio’s SWOT analysis: C5 inhibitor focus shifts stock outlookMay 24, 2025 | investing.comRallybio shareholders elect directors, ratify auditorMay 18, 2025 | uk.investing.comRallybio Reports First Quarter 2025 Financial Results and Provides Business UpdatesMay 9, 2025 | finance.yahoo.comRallybio to Present at the 2025 Citizens JMP Life Sciences ConferenceApril 29, 2025 | finance.yahoo.comJones Trading Downgrades Rallybio (RLYB)April 15, 2025 | msn.comRallybio downgraded to Hold from Buy at JonesResearchApril 14, 2025 | markets.businessinsider.comRallybio downgraded to In Line from Outperform at Evercore ISIApril 12, 2025 | markets.businessinsider.comRallybio (RLYB) was downgraded to a Hold Rating at H.C. WainwrightApril 10, 2025 | markets.businessinsider.comRallybio Stock Short Interest Report | NASDAQ:RLYB | BenzingaApril 9, 2025 | benzinga.comRallybio discontinues RLYB212 programApril 9, 2025 | markets.businessinsider.comRallybio sinks as it drops RLYB212 for prevention of FNAITApril 9, 2025 | thepharmaletter.comHC Wainwright & Co. Downgrades Rallybio (RLYB)April 9, 2025 | msn.comRLYB Ends Pregnancy-Related Rare Disease Program, Stock TanksApril 9, 2025 | zacks.comCitizens JMP downgrades Rallybio on RLYB212 discontinuationApril 9, 2025 | markets.businessinsider.comJMP Securities downgrades Rallybio (RLYB) to a HoldApril 9, 2025 | theglobeandmail.comRallybio Stock Plunges After Program For Pediatric Bleeding Disorder DisappointsApril 8, 2025 | benzinga.comRallybio Discontinues Development of Treatment for Prevention of Rare Immune DisorderApril 8, 2025 | marketwatch.comRallybio to Discontinue Development of RLYB212 for Prevention of FNAITApril 8, 2025 | finance.yahoo.comRallybio reports Q4 EPS (25c), consensus (30c)March 13, 2025 | markets.businessinsider.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimePRAX, ALLK, LRMR, and RLYB Company DescriptionsAllakos NASDAQ:ALLK$0.33 0.00 (0.00%) As of 05/15/2025Allakos Inc., a clinical stage biotechnology company, develops therapeutics that target immunomodulatory receptors present on immune effector cells in allergy, inflammatory, and proliferative diseases in the United States. The company's lead product candidate is AK006, which in a Phase I clinical trial for the treatment of chronic spontaneous urticaria (CSU) and other indications. The company was incorporated in 2012 and is headquartered in San Carlos, California.Larimar Therapeutics NASDAQ:LRMR$2.42 -0.17 (-6.56%) Closing price 04:00 PM EasternExtended Trading$2.45 +0.03 (+1.24%) As of 07:53 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Larimar Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing treatments for rare diseases using its novel cell penetrating peptide technology platform. Its lead product candidate is CTI-1601, which is in Phase 2 OLE clinical trial for the treatment of Friedreich's ataxia, a rare, progressive and fatal genetic disease. Larimar Therapeutics, Inc. is based in Bala Cynwyd, Pennsylvania.Praxis Precision Medicines NASDAQ:PRAX$41.63 -0.71 (-1.68%) Closing price 04:00 PM EasternExtended Trading$41.66 +0.02 (+0.06%) As of 06:12 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Praxis Precision Medicines, Inc., a clinical-stage biopharmaceutical company, engages in the development of therapies for central nervous system disorders characterized by neuronal excitation-inhibition imbalance. It is developing ulixacaltamide, a small molecule inhibitor of T-type calcium channels that is in Phase III clinical trial for the treatment of essential tremor; PRAX-562 for the treatment of pediatric patients with developmental and epileptic encephalopathies (DEE); and PRAX-628 to treat focal epilepsy. The company also develops PRAX-222 for the treatment of pediatric patients with early-onset SCN2A-DEE; PRAX-020 to treat KCNT1 related epilepsies; PRAX-080 for the treatment of PCDH19; and PRAX-090 and PRAX-100 for SYNGAP1 and SCN2A-LoF. It has a license agreement with RogCon Inc.; a research collaboration and license agreement with Ionis Pharmaceuticals, Inc.; a strategic collaboration and license agreement with UCB Biopharma SRL; and collaboration with The Florey Institute to develop three novel ASOs. The company was incorporated in 2015 and is based in Boston, Massachusetts.Rallybio NASDAQ:RLYB$0.31 +0.01 (+1.76%) Closing price 04:00 PM EasternExtended Trading$0.32 +0.01 (+2.28%) As of 07:04 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Rallybio Corporation, a clinical-stage biotechnology company, engages in development and commercialization of life-transforming therapies for patients suffering from severe and rare diseases. Its lead product candidate is RLYB212, a monoclonal anti-HPA-1a antibody that has completed Phase I clinical trial for the prevention of fetal and neonatal alloimmune thrombocytopenia (FNAIT); and RLYB211 for the prevention of FNAIT. The company is also developing RLYB114, a pegylated complement factor 5 (C5)-targeted Affibody molecule in preclinical development for the treatment of complement-mediated ophthalmic diseases; RLYB116, an inhibitor of complement component 5 (C5) to treat several diseases of complement dysregulation which has completed phase 1 trial; and RLYB331, a preclinical antibody, for the treatment of severe anemia with ineffective erythropoiesis and iron overload. It entered into a strategic alliance with AbCellera to discover, develop, and commercialize novel antibody-based therapeutics for rare diseases. Rallybio has collaboration with Exscientia for the development of small molecule therapeutics for rare diseases; and collaboration agreement with Johnson & Johnson to provide pregnant individuals therapeutic solutions at risk of fetal and neonatal alloimmune thrombocytopenia. The company was founded in 2018 and is headquartered in New Haven, Connecticut. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Microsoft Stock Holds Steady as AI Drives Workforce Shift Top International ETFs With Dividends and Market-Beating Returns D-Wave Goes International With South Korea Partnership BigBear.ai Poised to Benefit as Palantir Dominates AI Defense Kroger Stock Confirms Buy Signal as Uptrend Gains Strength Darden Stock Set to Sizzle After Blowout Q4 and $1B Buyback Alphabet’s Comeback: The Hidden Engines Powering Google New All-Time Highs Coming for Broadcom? Wall Street Says Yes Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
